Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

The FDA granted the drug Priority Review status just last week.

HCB Health acquires Topin & Associates

HCB Health acquires Topin & Associates

Austin-based HCB Health announced Tuesday its acquisition of Chicago indie agency Topin & Associates in an effort to push the borders of its client base.

Orexigen pleases shareholders, irks FDA

The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.

Haymarket Media acquires digital agency Group DCA

Haymarket Media acquires digital agency Group DCA

Haymarket purchased HCP-engagement specialist Group DCA and will operate the digital agency out of its custom medical communications division.

Five things for pharma marketers to know: Wednesday, March 4

Five things for pharma marketers to know: Wednesday, March 4

FDA adds new language to low-T drug labels; Afrezza's launch has a poor start, investors say; BMS acquires prostate-cancer vaccine in a deal worth $975 million.

Researchers find safety disclaimers do not register with consumers

The study indicates patients discount wording that indicates the FDA has not approved supplement claims.

Safety advocate, DOJ settle kickback allegations

The agreement includes a $1-million payment.

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

Holding company will now focus on two health networks—FCB Health and McCann Health

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

Analysts say head-to-head study results could make Kyprolis the lead treatment.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Drugmakers face increasing pressure on pricing from insurers and PBMs.

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

GAO: Dementia patients receiving harmful antipsychotics

Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Five things for pharma marketers to know: Friday, February 27

Five things for pharma marketers to know: Friday, February 27

Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.

Upward Move: Christine Petersen

Upward Move: Christine Petersen

PCORI explains how it will release comparative-effectiveness findings

PCORI explains how it will release comparative-effectiveness findings

The organization plans to publish a scientific and a lay abstract detailing study findings

Sanofi's new Lantus may not be the new Lantus

Sanofi's new Lantus may not be the new Lantus

Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.

Drugmaker shifts sales model to keep pace with formulary decision making

Drugmaker shifts sales model to keep pace with formulary decision making

Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.

Concerns over Vyvanse marketing: NYT

A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.

BI rare-disease awareness push slated for Saturday

Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.

Lilly Lantus biosimilar to hit EU

The EU will have access to the new medication in May.

CDC finds patients using more potent opioids

The survey shows the use of stronger-than-morphine painkillers has jumped.

Five things for pharma marketers to know: Thursday, February 26

Five things for pharma marketers to know: Thursday, February 26

Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.

Poll shows all ages seek digital health tools

Poll shows all ages seek digital health tools

Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.

Mobile carries WebMD forward

Mobile carries WebMD forward

Smartphones drove network traffic.

GSK re-launches OTC diet pill

The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.

Vice: Health search queries are being tracked

Search queries for common diseases on the websites for the CDC and WebMD, among others, are being sent to third-party corporations.

Five things for pharma marketers to know: Wednesday, February 25

Five things for pharma marketers to know: Wednesday, February 25

J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.

Top 3 formulary access takeaways for pharma

Top 3 formulary access takeaways for pharma

Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks

Global cancer drug market to grow to $111 billion by 2020: report

Global cancer drug market to grow to $111 billion by 2020: report

The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.

California ponders drug pricing reveal

Assemblyman David Chiu's bill would publish a drug's R&D and related costs.

UK doctors lobby for off-label Avastin use

Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Lilly peglispro delay may be boon for its biosimilar

Lilly peglispro delay may be boon for its biosimilar

The drugmaker wants to put the drug through additional liver-impact tests.

Survey shows docs shrug off Sunshine

A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.

AdAge: advertising's penalty box is empty

The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.

Five things for pharma marketers to know: Monday, February 23

Five things for pharma marketers to know: Monday, February 23

Valeant grabs Salix for $10.4 billion, BMS inks to collaborations deals and Pfizer lines up to have the first treatment for a rare lung disease.

Rosetta merges with Razorfish Healthware, forms new agency

Rosetta merges with Razorfish Healthware, forms new agency

Publicis Healthcare Communications Group announced Friday that Rosetta's healthcare engagement, creative and media businesses would be merged into Razorfish Healthware, creating Razorfish Health.

Five things for pharma marketers to know: Friday, February 20

Five things for pharma marketers to know: Friday, February 20

23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.

Poll highlights cholesterol knowledge gap

Poll highlights cholesterol knowledge gap

Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

An NIH study shows possible limit to Lucentis's appeal.

Newly discovered ALS gene may lead to new drug targets

A research collaboration between medical centers, drugmaker Biogen Idec and a biotechnology institute have identified a gene that could lead to new drug targets for sporadic amyotrophic lateral sclerosis—or Lou Gehrig's disease.

McNeil consumer president named HBA Woman of the Year

The Healthcare Businesswomen's Association named Denice Torres, president of J&J's McNeil Consumer Healthcare, as its 26th Woman of the Year.

Five things for pharma marketers to know: Thursday, February 19

Five things for pharma marketers to know: Thursday, February 19

Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.

W2O Group acquires Los Angeles boutique shop

W2O Group acquires Los Angeles boutique shop

The agency announced it will integrate with ACR2 Communications & Media in a bid to bolster its healthcare content offerings.

FDA expands Revlimid indication

Celgene's cancer drug is now approved for newly diagnosed patients.

AstraZeneca may give critic a seat at the table

Scientist Cori Bargmann's Twitter history makes the nomination a bit of a surprise.

Five things for pharma marketers to know: Wednesday, February 18

Five things for pharma marketers to know: Wednesday, February 18

Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.

Survey shows docs overestimate adherence

Survey shows docs overestimate adherence

A small physician survey shows doctors think their patients have higher adherence rates than the norm.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

Apple Watch ditches advanced health features: WSJ

Citing an unnamed source, the paper reports that Apple has abandoned some of the more advanced health monitoring features in its upcoming device, the Apple Watch.

Five things for pharma marketers to know: Tuesday, February 17

Five things for pharma marketers to know: Tuesday, February 17

Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.

Five things for pharma marketers to know: Friday, February 13

Five things for pharma marketers to know: Friday, February 13

FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.

Device maker pays feds $2.8M over physician false claims

Device maker pays feds $2.8M over physician false claims

Medtronic, as part of the settlement, will pay $602,000 to a whistleblower to settle charges it caused physicians to submit false claims to federal health programs.

Study shows impact of the "Angelina Jolie effect"

Study shows impact of the "Angelina Jolie effect"

AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.

Pfizer teams up with Alzheimer's foundation

Pfizer's academic research arm will work together with the Alzheimer's Drug Discovery Foundation to jointly invest in scientific research to identify clinical candidates for testing.

Print ads surface on programmatic exchanges

Time Inc., according to AdAge, has begun selling print ads for its magazines on exchanges.

Five things for pharma marketers to know: Thursday, February 12

Five things for pharma marketers to know: Thursday, February 12

Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).

Obama gives details on Precision Medicine Initiative

Obama gives details on Precision Medicine Initiative

President Barack Obama's recently unveiled Precision Medicine Initiative hopes to develop a new model of patient-driven research with the promise of accelerating biomedical discoveries and provide clinicians with new tools, knowledge, and therapies.

GSK launches Flonase OTC

GSK launches Flonase OTC

The initial push includes a behind-the-scenes Tumblr and broadcast plans are being finalized.

Sanofi lays off 100 at Boston R&D hub

The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.

Rite Aid buys PBM EnvisionRx for $2B

In a bid to compete with CVS Caremark, pharmacy retailer Rite Aid has purchased pharmacy- benefit manager Envision Pharmaceutical Services.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

FDA updates DTC ad policy on risk information

FDA updates DTC ad policy on risk information

FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."

OPDP finds many flaws with Luitpold video

OPDP finds many flaws with Luitpold video

The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.

Merck Januvia survey sparks ethics debate

A Merck survey that indicated distaste for British Columbia's decision to boot Januvia from the formulary has stirred up debate over bias.

Five things for pharma marketers to know: Tuesday, February 10

Five things for pharma marketers to know: Tuesday, February 10

FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.

PHCG global president leaves for Everyday Health

PHCG global president leaves for Everyday Health

Michael du Toit, founding member of Digitas, has been named president of health and wellness company Everyday Health.

Five things for pharma marketers to know: Monday, February 9

Five things for pharma marketers to know: Monday, February 9

Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.

Five things for pharma marketers to know: Friday, February 6

Five things for pharma marketers to know: Friday, February 6

Genentech Parkinson med encounters preliminary safety issues; Cigna gives Gilead's Harvoni preferred status over AbbVie's Viekira Pak; Valeant proposes $400 million bid to buy bankrupt Dendreon.

Pfizer's Hospira deal shores up established product division

Pfizer's Hospira deal shores up established product division

Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.

Survey shows cancer cause-effect awareness lacking

A survey showed patients are not really clear on what causes cancer.

Five things for pharma marketers to know: Thursday, February 5

Five things for pharma marketers to know: Thursday, February 5

FDA commissioner Margaret Hamburg has stepped down; Pfizer acquires Hospira for $15.2 billion, AstraZeneca buys Actavis's branded respiratory business.

FDA rescinds Merck HCV therapy's Breakthrough Designation

FDA rescinds Merck HCV therapy's Breakthrough Designation

The drugmaker announced in its earnings call Wednesday that the FDA has rescinded the company's Breakthrough Therapy designation, which could delay Merck's HCV doublet therapy launch from early to mid-2016.

Pfizer Ibrance is first approved CDK inhibitor

Pfizer Ibrance is first approved CDK inhibitor

The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.

FDA simplifies compassionate use application

The original required 26 bits of information and seven attachments.

Five things for pharma marketers to know: Wednesday, February 4

Five things for pharma marketers to know: Wednesday, February 4

One in three adults would rather not take a pill and have a shorter life span; Pfizer's next-gen breast-cancer drug nabs an early approval; Amgen's Humira biosimilar demonstrates clinical equivalence.

Education effort provides measles/pertussis cheat sheet

Education effort provides measles/pertussis cheat sheet

Measles outbreak news aside, doctors need help identifying illnesses vaccines have made uncommon.

Study says pharma may need profit-sustaining help

Study says pharma may need profit-sustaining help

Researchers say the golden-age of profits appears to be over, and the industry may need help funding innovation.

CDC: diabetes patient costs have doubled

The reason: higher prices and more services.

Ireland takes hard line on Rx prices

The health minister is threatening price-related legislation.

Five things for pharma marketers to know: Tuesday, February 3

Five things for pharma marketers to know: Tuesday, February 3

President Barack Obama states in budget proposal that government should negotiate drug pricing; J&J's rare cancer drug's review is expedited; inhalable insulin hits pharmacy shelves.

Education efforts key to Vyvanse success in BED, analyst says

Education efforts key to Vyvanse success in BED, analyst says

Shire's ADHD treatment Vyvanse won a label expansion into treating moderate-to-severe binge-eating disorder (BED) Friday. One analyst says that disease awareness and detailing efforts are crucial to the drug's commercial plans in the category.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Five things for pharma marketers to know: Monday, February 2

Five things for pharma marketers to know: Monday, February 2

Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.

Five things for pharma marketers to know: Friday, January 30

Five things for pharma marketers to know: Friday, January 30

Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.

MM&M launches inaugural Transforming Healthcare conference

MM&M launches inaugural Transforming Healthcare conference

You've seen the ads touting a "Day of Disruption." Here's the scoop on MM&M's first ever Transforming Healthcare conference.

At Work With . . .

At Work With . . .

Shane Mayer, VP, client services at InTouch Solutions

Upward Move

Upward Move

Cindy Whitehead, CEO, Sprout Pharmaceuticals

Researchers find payer discrimination

Researchers found that 25% of ACA-compliant plans put HIV drugs in the highest formulary tier.

Alexion, Treato shuffle staff

Alexion's CEO Leonard Bell is retiring, and TripAdvisor's Christine Peterson has joined Treato.

J&J's Imbruvica snares fourth indication

J&J's Imbruvica snares fourth indication

The label will now include Waldenstrom's macroglubulinemia.

Five things for pharma marketers to know: Thursday, January 29

Five things for pharma marketers to know: Thursday, January 29

Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.

Biogen adds football, basketball talent for MS campaign

Biogen adds football, basketball talent for MS campaign

MS drugmaker Biogen Idec drafted Tyler Campbell, son of NFL Hall of Fame running back Earl Campbell, and former Dallas Mavericks point guard Chris Wright to help inspire sufferers of multiple sclerosis.

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

Five things for pharma marketers to know: Wednesday, January 28

Five things for pharma marketers to know: Wednesday, January 28

Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.

Purdue's new Rx opioid hits market

Purdue's new Rx opioid hits market

Hysingla ER is ready for the marketplace, just two months after FDA approval.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters